Publications by authors named "Andre J Scheen"

Claim this Profile
E
Ecnoglutide, a biased GLP-1 receptor agonist as a potential new player for type 2 diabetes management?
André J Scheen

Lancet Diabetes Endocrinol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GLP-1-derived therapies and sarcopenia: plea for a specific focus on at risk special populations.
André J Scheen

Diabetes Metab· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GLP-1 receptor agonists, body composition, skeletal muscle and risk of sarcopaenia: from promising findings in animal models to debated concern in human studies.
André J Scheen

Diabetes Metab· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glucagon-like peptide-1 receptor agonists and alcohol use disorders: An emerging unexpected beneficial effect.
André J Scheen

Diabetes Obes Metab· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Weight loss therapy and addiction: Increased risk after bariatric surgery but reduced risk with GLP-1 receptor agonists.
André J Scheen

Diabetes Metab· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular and renal effects of the combination therapy of a GLP-1 receptor agonist and an SGLT2 inhibitor in observational real-life studies.
André J Scheen

Diabetes Metab· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy.
André J Scheen

Drugs· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sodium-glucose co-transporter type-2 inhibitors for hospitalised patients with COVID-19: safe but not protective.
André J Scheen

Lancet Diabetes Endocrinol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Not Available].
André J Scheen

Rev Med Suisse· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Innovative therapeutic drug combination for type 2 diabetes at cardiorenal risk].
André J Scheen, Nicolas Paquot

Rev Med Suisse· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Underuse of SGLT2 inhibitors in clinical practice].
André J Scheen

Rev Med Suisse· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile.
André J Scheen

Expert Opin Drug Saf· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular protection significantly depends on HbA1c improvement with GLP-1RAs but not with SGLT2 is in type 2 diabetes: A narrative review.
André J Scheen

Diabetes Metab· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review.
André J Scheen

Expert Rev Endocrinol Metab· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic, toxicological, and clinical considerations for the treatment of type 2 diabetes in patients with liver disease: a comprehensive update.
André J Scheen

Expert Opin Drug Metab Toxicol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?
André J Scheen

Expert Rev Clin Pharmacol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pragmatic trials, a step forward to assess cardiovascular efficacy of new glucose-lowering agents.
André J Scheen

Lancet Diabetes Endocrinol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies.
André J Scheen

Diabetes Metab· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Not Available].
André J Scheen

Rev Med Suisse· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Use of antidiabetic medications in the course of bariatric/metabolic surgery].
André J Scheen

Rev Med Suisse· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Effects of antidiabetic medications on metabolic-associated fatty liver disease].
André J Scheen

Rev Med Suisse· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of SGLT2 inhibitors after bariatric/metabolic surgery: Risk/benefit balance.
André J Scheen

Diabetes Metab· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Underuse of glucose-lowering medications associated with cardiorenal protection in type 2 diabetes: from delayed initiation to untimely discontinuation.
André J Scheen

Lancet Reg Health Eur· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolic disorders induced by psychotropic drugs.
André J Scheen

Ann Endocrinol (Paris)· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does race/ethnicity influence the impact of new glucose-lowering agents on cardiovascular outcomes?-a comparison between Asian versus White patients.
André J Scheen

Ann Transl Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis